Private investors: FCPR-FPCI

We apply our knowledge of French SMEs to help private investors who are looking for high-performance and meaningful investments

Private equity accessible to individual investors

  • Through its FCPR (Fonds Communs de Placement à Risque) and FPCI (Fonds Professionnels de Capital Investissement) range of private equity funds, Omnes Capital gives individual investors access to an asset class reserved for institutional investors

Boost portfolio returns

  • Invest in unlisted SMEs that create wealth and employment (bearing in mind that investing in private equity poses a liquidity risk)
  • Subscribe to an investment with high potential in exchange for the risk of capital loss
  • Diversify financial assets and secure tax incentives (sales exempt from capital gains tax) in return for freezing assets over a period of 10 years

Omnes’ expertise

  • 20 years’ experience
  • Rigorous selection of SMEs: high-performance French companies with a leadership position in their sector, genuine growth prospects, solid fundamentals and seasoned management team
  • Reasonable leverage and value creation underpinned by growth in portfolio companies’ net revenues (bearing in mind that this growth may not reflect final fund performance ; any investment presents risks)
  • Strong entrepreneurial culture among management teams, who share the same vision as company executives
  • Direct access to the management team
  • Meetings with portfolio companies entrepreneurs and detailed reporting provided
Key figures
20
years’
experience
..
Dedicated offer
to private investors
NewsRoom
Publication
Omnes Newsletter no 32: Philippe Barre, Founder of Darwin
Press release
11 April 2019
NH TherAguix, a start-up specializing in nanomedicine for cancer radiotherapy, announces a €13 million round of fundraising, led by Bpifrance

NH TherAguix, a start-up specializing in nanomedicine for cancer radiotherapy, announces a €13 million round of fundraising, led by Bpifrance
Press release
09 April 2019
Appointments within Omnes: Omnes welcomes five newcomers as Director, Principal, Analyst, Middle Office Managers, and promotes four Principals
Appointments within Omnes: Omnes welcomes five newcomers as Director, Principal, Analyst, Middle Office Managers, and promotes four Principals
Press release
03 April 2019
AgomAb Therapeutics Completes Euros 21m Series A Financing
AgomAb Therapeutics Completes Euros 21m Series A Financing
Publication
Omnes Newsletter no 32: VC news H2 2017
Press release
19 March 2019
Omnes announces a 15% investor net IRR on its Capenergie 2 fund, focused on renewable energy

Omnes announces a 15% investor net IRR on its Capenergie 2 fund, focused on renewable energy

Pages